EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Effectiveness of combination tocilizumab and glucocorticoids as an induction therapy in patients with Takayasu arteritis: An observational study

Shuhei Yoshida, Eiji Suzuki, Haruki Matsumoto, Kohei Yokose, Yuya Fujita, Jumpei Temmoku, Naoki Matsuoka, Makiko Yashiro-Furuya, Tomoyuki Asano, Shuzo Sato iD, Hiroshi Watanabe, Kiyoshi Migita

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac033 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Shuhei Yoshida und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan. Hauptthemen laut MEDLINE: Glucocorticoids, Takayasu Arteritis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Japan Grant-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of tocilizumab (TCZ) in the treatment of Takayasu arteritis (TA) was demonstrated in randomized controlled trials. The objective of this study was to analyse the effectiveness of combining TCZ with glucocorticoids (GC) as induction therapy in patients with TA.

Method

This was a retrospective observational study including 32 patients with newly diagnosed TA. Clinical effectiveness of TCZ in maintaining relapse-free remission and GC-tapering were compared between patients who were treated with TCZ plus GC and those who were treated with GC with or without immunosuppressants.

Results

The study comprised 32 patients (27 women/5 men) with a median age of 25.5 years (range, 13–72). In the TCZ group (n = 14), patients received TCZ in combination with GC as an induction therapy. In the non-TCZ group (n = 18), patients were treated with single-agent GC or GC plus immunosuppressant. In the matched analysis, relapse-free survival rate was significantly higher in the TCZ group as compared to the non-TCZ group during GC taper.

Conclusion

TCZ, in combination with GC, would be an effective alternative induction regimen for patients with TA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucocorticoidsTakayasu ArteritisMaleHumansFemaleAdolescentYoung AdultAdultMiddle AgedAgedInduction ChemotherapyImmunosuppressive AgentsTreatment OutcomeRecurrenceAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

GlucocorticoidsTakayasu arteritisimmunosuppressantinterleukin-6tocilizumab

Substanzen

GlucocorticoidsImmunosuppressive AgentstocilizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Department of Rheumatology, Ohta-Nishinouchi Hospital, Fukushima, Japan.

ORCID-Profile: Shuzo Sato

Förderung

  • Japan Grant-in-Aid for Scientific Research

Zitieren

APA

Yoshida, S., Suzuki, E., Matsumoto, H., Yokose, K., Fujita, Y., Temmoku, J., Matsuoka, N., Yashiro-Furuya, M., Asano, T., Sato, S., Watanabe, H., & Migita, K. (2023). Effectiveness of combination tocilizumab and glucocorticoids as an induction therapy in patients with Takayasu arteritis: An observational study. Modern Rheumatology. https://doi.org/10.1093/mr/roac033

Vancouver

Yoshida S, Suzuki E, Matsumoto H, Yokose K, Fujita Y, Temmoku J, et al. Effectiveness of combination tocilizumab and glucocorticoids as an induction therapy in patients with Takayasu arteritis: An observational study. Modern Rheumatology. 2023. doi:10.1093/mr/roac033

BibTeX
@article{Yoshida2023,
  author = {Yoshida, Shuhei and Suzuki, Eiji and Matsumoto, Haruki and Yokose, Kohei and Fujita, Yuya and Temmoku, Jumpei and Matsuoka, Naoki and Yashiro-Furuya, Makiko and Asano, Tomoyuki and Sato, Shuzo and Watanabe, Hiroshi and Migita, Kiyoshi},
  title = {Effectiveness of combination tocilizumab and glucocorticoids as an induction therapy in patients with Takayasu arteritis: An observational study},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac033}
}
Kostenlos starten →